Breast tumor kinase (Brk) is a non-receptor tyrosine kinase distantly related to the Src family kinase. It is expressed in more than 60% of breast tumors, but the biological role of this kinase remains to be determined. Only a limited number of substates have been identified for Brk, and the link of Brk to tumorigenesis remains largely unknown. In this study, we provide evidence that the signal transducer and activator of transcription 3, STAT3, is a physiological target of Brk. Activation of STAT3 previously has been linked to oncogenesis, and results in this study demonstrate that STAT3 is tyrosine phosphorylated and transcriptionally activated in cells expressing endogenous Brk. Signal transducer and activator of transcription 3 is specifically targeted since other STAT members are not responsive to Brk expression. Signal transducer and activator of transcription 3 activation requires the catalytic activity of Brk, and expression of both STAT3 and Brk stimulate cellular proliferation. In addition, we have identified a negative regulator of Brk, the suppressor of cytokine signaling, SOCS3. The SOCS3 protein is known to block signaling mediated by cytokine receptors, and here we find that SOCS3 is able to repress the activity of the Brk nonreceptor tyrosine kinase.
Introduction
Breast tumor kinase (Brk) is a non-receptor tyrosine kinase originally isolated from a metastatic human breast carcinoma (Mitchell et al., 1994) . Subsequent characterization of Brk showed it to be present in approximately 60% of human breast tumors, yet absent in normal or fibrocystic mammary tissues. It has now been shown to be expressed in other cancers including metastatic melanomas, and colon and prostate tumors Easty et al., 1997; Llor et al., 1999; Derry et al., 2003) . The murine homolog of Brk has been found in normal differentiating epithelial cells of the skin, and epithelial cells lining the gastrointestinal tract and the prostate lumen. However, its expression is undetectable in mammary tissues at any stage of development (Siyanova et al., 1994; Vasioukhin et al., 1995) . Overexpression of Brk was found to sensitize mammary epithelial cells to the mitogenic effect of epidermal growth factor (EGF) and enhance the coupling of EGF and PI3 kinase pathways via erbB3 phosphorylation (Kamalati et al., 1996 (Kamalati et al., , 2000 . Breast tumor kinase has also been reported to associate with insulin receptor substrate 4 (IRS4), suggesting a potential role of Brk in insulin-like growth factor 1-induced proliferation (Qiu et al., 2005) . Collectively, these findings indicate elevated expression of Brk may promote abnormal growth below the threshold that proliferative growth factors exert their mitogenic effects.
Breast tumor kinase displays 46% sequence homology to c-Src kinase and a similar domain arrangement (Mitchell et al., 1994; Serfas & Tyner, 2003) . Breast tumor kinase possesses an Src Homology 3 (SH3), an Src Homology 2 (SH2), and a tyrosine kinase catalytic domain, but it lacks an amino myristoylation site for membrane targeting. Molecular characterization confirms that Brk is regulated by autophosphorylation and autoinhibition, involving both the SH3 and SH2 domains, whereas substrate recognition is mediated mainly by the SH3 domain (Qiu & Miller, 2002 Kim and Lee, 2005) . To date, only five substrates have been identified for Brk, and the downstream events triggered by Brk largely remain to be elucidated. One Brk substrate is signal-transducing adaptor protein-2 (STAP-2) that has been implicated in modulating the activity of some members of the signal transducer and activator of transcription (STAT) family (Mitchell et al., 2000; Minoguchi et al., 2003) .
Signal transducers and activators of transcription are a family of transcription factors that were initially discovered as key mediators of cytokine signaling (Akira, 1999; Darnell et al., 1994; Decker, 1999; Ihle, 2001) . Subsequently a few of the STATs were found to be activated by growth factors such as epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) in addition to cytokines (Darnell, 1997; Levy & Darnell, 2002) . The STAT proteins have been shown to play significant roles in immune function, and also in development, cellular proliferation, and survival. There are seven mammalian STATs that respond to different subsets of cytokines. All seven STATs contain an SH2 domain and a specific tyrosine residue near the carboxyl terminus that is phosphorylated in response to hormone stimulation. Phosphorylation of this tyrosine alters the conformation of the STAT molecule and promotes dimerization via reciprocal SH2-phosphotyrosine interactions. The phosphorylated STAT dimers gain the ability to bind specific DNA targets and induce expression of responsive genes.
Individual functions of the STAT members have been revealed by targeted gene disruption. Signal transducers and activators of transcription knockout animals display specific phenotypes, but only the STAT3 genetic knockout results in embryonic lethality, attesting to its vital role in cell survival (Takeda et al., 1997) . Signal transducers and activators of transcription tyrosine phosphorylation has been causally linked to tumorigenesis in a number of recent studies. Cells expressing STAT3 with a gain-of-function mutation are tumorigenic in nude mice (Bromberg et al., 1999) . Constitutive STAT3 activation has been found in multiple types of tumors, including prostate cancer, lung cancer, breast cancer, head and neck tumors, central nervous system tumors, lymphomas, and leukemia, and also in cells transformed by oncogenic tyrosine kinases such as v-Src, v-Ros, Bcr-Abl, and Tel-JAK (Benekli et al., 2003; Bowman et al., 2000; Bromberg, 2002; Coppo et al., 2003; Lacronique et al., 2000; Olayioye et al., 1999; Yu et al., 1995) . Recently, studies in a lymphoma mouse model have demonstrated that suppression of STAT3 triggers tumor apoptosis and regression, validating it as a target of cancer therapeutics (Charile et al., 2005) .
In this study, we evaluated STAT3 activation in breast tumor cells and found that STAT3 phosphorylation is elevated in cells that express Brk. Exogenous expression of Brk induces the tyrosine phosphorylation and transcriptional activation of STAT3, but not other STAT molecules. We also provide evidence that STAT3 is a direct substrate of Brk, and that the ability of Brk to phosphorylate STAT3 can be inhibited by a specific member of the suppressor of cytokine signaling, SOCS3.
Results

STAT3 tyrosine phosphorylation in breast tumor cell lines expressing Brk
The Brk protein has been detected in a number of breast cancer lines, and since phosphorylated STAT3 has been found in a variety of tumor tissues, we evaluated STAT3 as a target for Brk . We first examined a panel of breast tumor cell lines for the presence of Brk and STAT3 tyrosine phosphorylation ( Figure 1a) . To decrease the potential of STAT3 phosphorylation by growth factors in the media, the cells were serum-starved for 24 h prior to analysis. Breast tumor kinase protein expression was detected in MDA-MB-231, T47D, and MDA-MB-453 cells by Western blot, and STAT3 was also found to be tyrosine phosphorylated in these cells. The results indicated that cells expressing detectable Brk also expressed tyrosinephosphorylated STAT3.
These breast tumor cells were derived from patients with different genetic backgrounds, and therefore other kinases may have contributed to disease progression and STAT3 phosphorylation. For this reason, we introduced Brk into breast tumor cells and tested the effect on STAT-dependent gene expression. Tyrosine-phosphorylated STAT dimers recognize a DNA sequence designated the interferon-g activation sequence (GAS) since the DNA target was initially identified in interferon-g responsive genes. MCF7 cells that express very low or undetectable levels of Brk were co-transfected with a luciferase reporter gene regulated by a GAS element and increasing amounts of plasmids encoding Brk (Figure 1b ). Increasing expression of Brk resulted in a dose-dependent response of the STAT-response reporter gene. The level of STAT3 tyrosine phosphorylation also increased with increasing Brk overexpression (data not shown). These results supported the possibility that STAT3 is a target of Brk. MCF7 cells were co-transfected with a GAS site-driven luciferase construct and increasing amounts of Brk. Following serum starvation for 24 h, lysates were prepared and used to measure luciferase reporter gene activity. The data represent two independent experiments.
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Enzymatic activity of Brk is required for STAT3 phosphorylation and induction of STAT-dependent gene expression Mutational analyses have identified two residues in Brk that are critical for its regulation and enzymatic activity (Mitchell et al., 1994; Kamalati et al., 1996) . Phosphorylation of the tyrosine 447 residue (Y447) appears to exert a negative regulatory effect on the enzymatic activity. The Y447F mutation abrogates this inhibition resulting in a constitutively active kinase. Lysine 219 is required for the enzymatic activity of Brk, and the K219M mutation abolishes kinase activity. Breast tumor kinase has been shown to be able to transform fibroblasts to anchorage-independent growth, and this ability relies on its enzymatic activity. However, it is also reported that the Brk K219M mutant is capable of promoting proliferation of breast tumor cells, suggesting that Brk may function as a scaffold molecule in other unidentified signaling pathways independent of its enzymatic activity (Harvey & Crompton, 2003) . To determine whether the enzymatic activity of Brk is required for STAT3 phosphorylation, we tested the effect of Brk mutations ( Figure 2a ). Wild-type (wt) Brk, the kinase-dead Brk mutant K219M, or the hyperactive active mutant Y447F were introduced into HeLa cells, the cells were subsequently serum starved for 24 h, and phosphorylation of endogenous STAT3 was detected by Western blot. Wildtype Brk stimulated endogenous STAT3 tyrosine phosphorylation, whereas the K219M mutation clearly failed to induce any detectable phosphorylation of STAT3, and the Y447F mutant induced STAT3 phosphorylation about threefold higher than that induced by wt Brk. The data suggest that the enzymatic activity of Brk is required for its ability to phosphorylate STAT3.
The phosphorylation state of STAT3 in response to wt or mutated Brk correlated with STAT-dependent gene expression. Plasmids encoding wt Brk, Y477F, or K219M were co-expressed with the STAT-dependent luciferase reporter gene in HeLa cells and the induced gene expression correlated with enzymatic activity of the Brk proteins ( Figure 2b) . To eliminate the possible contribution of the STAT1 family member in response to Brk, U3A cells were tested that are defective in STAT1 expression (Figure 2c ). The transcriptional response to Brk was the same in HeLa and U3A cells. The K219M mutation was not able to induce STATdependent gene expression detected by the reporter assay, while the Y447F mutation induced expression approximately twofold greater than wt Brk (Figure 2b ). These results indicated that the enzymatic activity of Brk is required to induce STAT3 phosphorylation and STAT-dependent gene expression.
Specificity of STAT3 phosphorylation by Brk
The GAS element that regulates the promoter of the luciferase reporter gene can be recognized by several of the STAT homodimers or heterodimers. The results of gene expression in U3A cells that are deficient in STAT1 decreased the possibility that STAT1 was involved in the gene response. To evaluate the possible contribution of other STATs that might be present in the cells, the ability of Brk to phosphorylate STAT1, STAT2, STAT3, STAT5, and STAT6 was tested. Plasmids encoding wt or mutated forms of Brk were co-expressed with various STAT plasmids, and the cells were subsequently serum-starved for 24 h. Protein lysates were prepared from these cells and the status of tyrosine phosphorylation of the STAT molecules was analysed by Western blot with specific phosphotyrosine antibodies that recognize each individual STAT protein ( Figure 3 ). Positive controls with growth factors (EGF) or cytokines (IFN-a and IL-4) that are known to stimulate phosphorylation of particular STATs were included. Signal transducer and activator of transcription 3 is clearly phosphorylated in response to wt Brk and the active Y447F mutation, and this is unique to To further confirm the unique role of STAT3 in mediating STAT-dependent gene expression in response to wt Brk, we evaluated STAT3 null murine embryonic fibroblasts (stat3À/À MEFs). The STAT-dependent GAS-luciferase reporter gene was introduced into stat3À/À MEFs with or without the Brk gene and either a control vector or the wt STAT3 gene or a gene encoding a tyrosine mutation of STAT3, Y750F (Figure 4a ). Breast tumor kinase expression in the absence of STAT3 did not induce the GAS-luciferase reporter gene. Expression of wt STAT3 in the absence of expressed Brk caused a modest gene induction. However, there was a synergistic effect of Brk and wt STAT3, resulting in nearly a 10-fold induction of gene expression. The tyrosine mutation of STAT3 (Y705F) that cannot be phosphorylated in response to cytokines, growth factors, or Brk cannot cooperate with Brk to induce specific gene expression. These results clearly identify STAT3 as a downstream target of Brk.
As there is evidence for a link between Brk and STAT3 activity and cellular proliferation, we evaluated the effect of these molecules on cellular proliferation of the MEFs. Stat3À/À or wt cells were transduced with retroviruses expressing either green fluorescence protein (GFP), or Brk and GFP and selected for GFP expression by flow cytometry. For the proliferation assay, a similar number of cells were plated, and the viability of the cultures was measured by the ability of mitochondrial enzymes to cleave the membrane-permeable compound MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). The growth of the cell cultures was measured during the course of 5 days by the MTT assay (Figure 4b ). Cells lacking both Brk and STAT3 were the slowest growing cultures, whereas a cooperative effect promoting proliferation was evident in cells expressing both Brk and STAT3. Cells expressing only Brk or only STAT3 did have a growth advantage, but the presence of both proteins provided maximal proliferation. 
STAT3 as a direct substrate of Brk
The correlation of Brk expression with STAT3 tyrosine phosphorylation does not ensure that STAT3 is a direct substrate of STAT3. To eliminate the possibility that STAT3 is phosphorylated in response to autocrine interleukin-6 (IL-6), we tested the effect of inhibition of the JAK-STAT3 pathway stimulated by IL-6. The reason for testing this pathway is that one of the few direct substrates identified for Brk is paxillin, and phosphorylated paxillin activates Rac1 (Chen et al., 2004) . Our previous study established the ability of activated Rac1 to induce the production and autocrine action of IL-6 leading to the phosphorylation of STAT3. For this reason, we evaluated the activation of STAT3 in response to Brk or to the activated form of Rac1, Rac1 V12 (Figure 5a ). HeLa cells were co-transfected with plasmids encoding STAT3 and Rac1 V12 (left panel) or STAT3 and Brk (right panel) and serum-starved for 24 h. HeLa cells express insufficient endogenous IL-6 receptors for signaling and therefore soluble IL-6 receptors (IL6R) were added to the culture media to ensure IL-6 signal transduction. Consistent with our previous study, the active mutant Rac1 V12 effectively induced STAT3 phosphorylation with the addition of soluble IL-6 receptor, and the presence of a neutralizing IL-6 receptor antibody (anti-IL6R) significantly reduced phosphorylation of STAT3 (left panel). In contrast, Brk induced robust STAT3 phosphorylation in the absence of soluble IL-6 receptor, and this phosphorylation was not affected by the presence of neutralizing IL-6 receptor antibody (right panel). These results suggest that STAT3 may be a direct substrate for Brk.
To test more directly the ability of Brk to phosphorylate STAT3, we performed an in vitro kinase assay with purified Brk and STAT3 proteins (Figure 5b ). Fulllength STAT3 was purified as a GST fusion from bacteria that lack tyrosine kinases. Wild-type Brk and the kinase-dead Brk K219M mutation, both tagged with a V5 epitope, were expressed in COS1 cells and isolated by immunoprecipitation with anti-V5 antibody immobilized on protein G agarose beads. Protein lysate from cells transfected with only the V5 epitope vector was used as a control for non-specific activity associated with the anti-V5 immunocomplexes. In addition, nonspecific antibody (MOPC) was used for immunoprecipitations of lysates expressing wt Brk as another negative control. The antibody-bead immunocomplexes were incubated with bacterial GST-STAT3 in the absence or presence of ATP at 301C for 1 h, and tyrosine phosphorylation of STAT3 was detected by Western blot with a specific anti-STAT3 phosphotyrosine antibody. The results clearly indicated that wt Brk, but not the kinase-dead K219 mutant, effectively phosphorylated STAT3 in vitro (Figure 5b) . In a similar assay, the ability of purified recombinant Brk to phosphorylate bacterially expressed GST-STAT3 was tested. The purified Brk protein was able to phosphorylate STAT3 on Y705 in a dose-dependent manner (Figure 5c ). The phosphorylation was dependent on the presence of ATP, providing evidence that STAT3 is a Figure 5 Evidence that STAT3 is a direct substrate for Brk. (a) STAT3 activation by Brk is not inhibited by neutralizing IL-6 receptor antibodies. HeLa cells were transfected with STAT3 and T7-tagged Rac1 V12 (left panel), or STAT3 and Brk (right panel). 10 h after transfection, cells were serum-starved in the absence or presence of soluble IL-6 receptor with or without neutralizing IL-6 receptor antibody. Lysates were prepared and subjected to SDS-PAGE and Western blot analysis with specific antibodies to STAT3 phosphotyrosine, STAT3, T7, or Brk. (b) In vitro kinase assay with STAT3 and Brk. Lysates from cells expressing the control vector, wild-type (WT) or kinase-dead mutant Brk (K219M) tagged with the V5 epitope were immunoprecipitated with V5 or MOPC antibodies, and the immunocomplexes were captured by Protein G agarose beads. After extensive washes, these beads were incubated with bacterially expressed and purified GST-STAT3 immobilized on glutathione agarose beads in the absence or presence of ATP at 301C for 1 h. Proteins eluted from agarose beads were analysed by SDS-PAGE and Western blot with specific STAT3 phosphotyrosine and Brk antibodies. Equal input of purified STAT3 in each reaction was confirmed by staining the blotting membrane with Ponseau S prior to blocking (middle panel). (c) In vitro kinase assay with STAT3 and recombinant Brk. Recombinant Brk protein (0.2 or 1 mg) was immobilized on Talon beads and incubated with bacterially expressed and purified GST-STAT3 immobilized on glutathione agarose beads in the absence or presence of ATP at 301C for 1 h. Eluted proteins were analysed by SDS-PAGE and Western blot with specific STAT3 phosphotyrosine and Brk antibodies. Equal input of purified STAT3 in each reaction was confirmed by Ponseau S staining (bottom panel).
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SOCS3 inhibits Brk phosphorylation of STAT3
Negative feedback regulation plays a critical role in normal homeostasis, and negative regulation of JAK-STAT signal transduction is mediated by a family of proteins called suppressors of cytokine signaling (SOCS) (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . One of these proteins, SOCS3, was discovered by its ability to block IL-6 signaling and JAK tyrosine phosphorylation of STAT3 (Nicholson et al., 1999) . For this reason, the effect of SOCS3 was tested for its ability to block STAT3 tyrosine phosphorylation and transcriptional activity induced by the non-receptor kinase, Brk (Figure 6 ). Cells were transfected with genes encoding STAT3-GFP and Brk, with or without cotransfected SOCS3. Signal transducer and activator of transcription 3 phosphorylation was evaluated by Western blot with STAT3 phosphotyrosine-specific antibody ( Figure 6a ). The results indicated that SOCS3 expression effectively inhibited Brk-induced STAT3 phosphorylation (lanes 5 and 6). A comparative positive control was included to demonstrate the effect of SOCS3 on STAT3 phosphorylation stimulated by JAK activation in response to IFNa signaling (lanes 3 and 4). The inhibitory effect of SOSC3 was also evident by the inhibition of STAT3-dependent reporter gene expression stimulated by Brk (Figure 6b ). The SOCS3 protein abolished the GAS-luciferase gene induced by STAT3 not only in response to IFN-a signaling but also in response to Brk (Figure 6b ).
Discussion
Breast tumor kinase is expressed in more than 60% of breast tumor cells, and for this reason it has been linked to the development of breast cancer. Little is known of the downstream effectors of Brk, but five substrates have been described, RNA-binding protein Src Associated in Mitosis 68 (Sam68) (Derry et al., 2000; Coyle et al., 2003) , Sam68-like proteins SLM-1 and SLM-2 (Haegebarth et al., 2004) , and adaptor proteins STAP-2 and paxillin (Mitchell et al., 2000; Chen et al., 2004) . The studies in this report have added another substrate to this list, the STAT3 transcription factor. Signal transducer and activator of transcription 3 is known to act as an oncogene in a constitutively active form, and tyrosine phosphorylation of STAT3 is correlated with breast cancer. As a transcription factor, the oncogenic potential of phosphorylated STAT3 is mediated by the function of its target genes. Documented STAT3 target genes that are associated with proliferation or inhibition of apoptosis include c-myc, cyclin D1, bcl-xl, and akt, as well as the gene encoding vascular endothelial growth factor (VEGF) which plays a role in angiogenesis during breast tumor development. Further investigation as to whether any of these STAT3 target genes are required for the proliferative response to Brk should provide insight to a Brk-STAT3 link in breast tumor formation.
The molecular switch that leads to induction of Brk expression in mammary tissues during malignant transformation remains to be determined. The 5 0 promoter region of the brk gene has been characterized and contains putative cis-acting elements for NF-kB, STAT, AP2, and Sp1 Kang et al., 2002) . It is not known whether activation of any one or a combination of these transcription factors is sufficient to induce Brk expression. The expression of Brk does not appear to correlate with the malignancy of the breast tumor. Breast tumor kinase is expressed in both highly invasive breast tumor cells such as MDA-MB-231, and less aggressive tumor cells such as T47D (van den Brule et al., 1992) . It is possible that activation of STAT3 by Brk contributes to the uncontrolled growth Figure 6 Evidence that SOCS3 inhibits Brk-induced STAT3 activation. (a) Inhibition of Brk-induced STAT3 phosphorylation by SOCS3 overexpression. COS1 cells were co-transfected with STAT3-GFP and Brk with or without SOCS3 and serum-starved for 24 h. Control cells were transfected with STAT3-GFP and SOCS3 and serum-starved for 24 h followed by 30 min IFNa treatment. Lysates were prepared and analysed by SDS-PAGE and Western blot with specific antibodies to STAT3 phosphotyrosine, GFP (to detect transfected STAT3), V5 (to detect Brk), or Flag (to detect SOCS3) on the same membrane. (b) Suppression of STAT3-dependent gene expression induced by Brk. HeLa cells were cotranfected with a GAS-site-driven reporter construct and wt Brk with or without SOCS3. Control cells were transfected with the reporter construct with or without SOCS3, and treated with IFNa for 6 h. Lysates were prepared following serum starvation and used to measure luciferase activity. The data represent two independent experiments.
STAT3 tyrosine phosphorylation by Brk L Liu et al and transformed phenotype during early stages of breast tumor development, and at later stages phosphorylation of paxillin and activation of Rac1 directly contributes to metastasis and invasion of tumor cells into other tissues. Cellular localization of Brk may contribute to substrate preference. Studies have found Brk to reside primarily in the nucleus of normal prostate epithelial cells and welldifferentiated tumor cells; however, in poorly differentiated prostate tumors, Brk localizes more prominently in the cytoplasm (Derry et al., 2003) . The cause of this altered localization of Brk remains to be determined, but it may contribute in the development of prostate neoplasia. Mammalian cells are highly compartmentalized and co-localization is a requisite for protein interaction. We have shown previously that STAT3 is predominantly nuclear in a latent state (Liu et al., 2005) , whereas paxillin and Rac1 are known to localize mainly in the cytoplasm. It can be speculated that STAT3 is a preferential substrate for Brk at early stages of tumor development, and STAT3 activation leads to the accumulation of oncoproteins such as cMyc that contribute to tumorigenesis.
SOCS3 protein is a known negative modulator of JAK-STAT signaling stimulated by the IL-6 cytokine family. The SOCS3 gene is induced in response to STAT3 activation and functions to block JAK tyrosine phosphorylation of STAT3. The SOCS proteins possess two functional domains, a central SH2 domain that recognizes phosphotyrosine residues, and a carboxyl domain termed an SOCS box that can physically interact with E3 ubiquitin ligase complexes (Krebs & Hilton, 2000) . SOCS3 binds to phosphorylated tyrosine residues on the gp130 subunit of the IL-6 family of receptors via its SH2 domain (Nicholson et al., 1999) . This binding prevents activation of the receptorassociated JAKs, thereby inhibiting the phosphorylation of STAT3. SOCS3 also appears to be able to associate directly with JAK2 and inhibit phosphorylation of STATs (Sasaki et al., 2000) . Our studies have found that SOCS3 is able to inhibit the ability of a nonreceptor kinase, Brk, to phosphorylate STAT3. The mechanism by which SOCS3 suppresses Brk activity remains to be determined, and may involve inhibition of enzymatic activity and/or substrate recognition. Whatever the mechanism, the results reveal that SOCS3 action is not restricted to JAK-STAT signaling, and therefore may potentially block Brk activity in breast tumors.
Signal transducer and activator of transcription 3 has attracted attention as a drug target for cancer therapeutics (Chiarle et al., 2005; Garcia et al., 2001; Leong et al., 2003; Niu et al., 2002) . A dominant negative form of STAT3 has been reported to inhibit proliferation and promote apoptosis of breast tumor cells and melanoma cells ex vivo. Introduction of double-stranded decoy oligonucleotides that closely resemble STAT3 target DNA sites specifically inhibited STAT3 activation and abrogated growth of head and neck tumor cells. Furthermore, it has been demonstrated recently that ablation of STAT3 either by genetic approaches or antisense oligonucleotides significantly impaired lymphoma growth in vivo. These results have endorsed STAT3 as a target for effective cancer drugs. Protein tyrosine kinases (PTKs) have been extensively studied in breast cancer development, and the efficacy of PTK inhibitors has been evidenced with the effectiveness of antibody therapy against the Her2 receptor PTK (Hennipman et al., 1989) . Signal transducer and activator of transcription 3 is a common downstream effector molecule for many receptor PTKs and oncogenic tyrosine kinase, and as we show in this report it is a target of the non-receptor PTK. The DNA-binding activity of STAT3 has been detected in many breast tumors, and targeted STAT3 therapies could have a broader application for the inhibition of tyrosine kinases that contribute to breast cancer.
Materials and methods
Cell culture and reagents HeLa, COS1, MCF7, MDA-MB-435 s, MDA-MB-231, MDA-MB-453, and T47D cells were cultured according to guidelines of ATCC. The STAT3 null MEFs and control wt MEFs were cultured as described. Recombinant human IFN-a (gift from Hoffman-LaRoche, Nutley, NJ, USA) was used at 1000 U/ml. Human EGF (Sigma, St Louis, MO, USA) and IL-4 (gift from Schering Plough, Kenilworth, NJ, USA) were used at 10 ng/ ml. Soluble IL-6 receptor (R&D Systems, Minneapolis, MN, USA) was used at 1 ng/ml and the neutralizing IL-6 receptor antibody (BIOSOURCE, Camarillo, CA, USA) was used at 10 ng/ml. DNA transfections were performed with Fugene-6 (Roche, Indianapolis, IN, USA). Anti-phosphotyrosine STAT3 (B7, Santa Cruz, CA, USA), anti-STAT3 (H190, Santa Cruz), anti-Brk (Santa Cruz, CA, USA), and anti-GFP (Roche) were used at a 1:1000 dilution in Western blot analysis. Anti-T7 (Novagen, Madison, WI, USA), anti-V5 (Invitrogen, Carlsbad, CA, USA), and anti-Flag (M2, Sigma) were used at a 1:5000 dilution in Western blot analysis.
Plasmids
The GAS luciferase reporter plasmid, CMV/Brk, CMV/Brk Y447F, CMV/Brk K219M, Rac1 V12, and SOCS3-Flag plasmids have been previously described (Faruqi et al., 2001; Qiu and Miller, 2004) . The STAT1-GFP, STAT2-GFP, STAT3-GFP, STAT5-GFP, and STAT6-GFP were previously described or generated by cloning the STAT cDNA without stop codons into the pEGFP-N1 vector (Banninger and Reich, 2004; Liu et al., 2005; McBride et al., 2000) . The wt or K219M mutant of Brk cDNA without a stop codon amplified by polymerase chian reaction (PCR) and cloned into the pEF1/ V5-HisA vector (Invitrogen) to generate to V5 epitope-tagged Brk mammalian expression constructs. The STAT3 cDNA was cloned into the pGEX-KG vector in frame with GST for bacterial expression and purification.
Luciferase reporter assay
The STAT3 null MEFs were seeded in six-well plates (2 Â 10 5 cells/well) and transfected with Fugene at a 1:3 DNA:Fugene ratio, and all other cell lines were seeded in 12-well plates (1 Â 10 5 cells/well) and transfected at a 1:2 DNA:Fugene ratio. Cells were transfected in duplicate with protein expression plasmids, GAS luciferase reporter plasmid, and a promoterless renilla luciferase plasmid, pRL-null, for transfection control. Transfected cells were serum-starved for 24 h before lysis. Preparation of cell lysates and measurement of light units STAT3 tyrosine phosphorylation by Brk L Liu et al were carried out using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) following the manufacturer's instructions. Relative Light Units were calculated as (firefly luciferase activity/renilla luciferase activity) Â 1000.
Low-serum growth assay Brk-V5 cDNA was cloned into the REBNA/IRESGFP vector. Phoenix E cells were transfected with this construct or the control vectors were used to produce retrovirus. The STAT3À/À or the STAT3 þ / þ MEFs were infected with Brk-or GFPexpressing virus in the presence of 5 mg/ml Sequabrene (Sigma) and stable infectants were sorted by flow cytometry and maintained in DMEM containing 10% calf serum. For the assay of growth, 5000 cells were seeded in 24-well plates in growth media and the media were adjusted to DMEM containing 3% calf serum as the cells started attaching to the bottom (B5 h). The point of serum reduction was designated day 0 and the proliferation during was measured every 24 h for 5 days by MTT assay essentially as described (Mossman, 1983) .
Bacterial expression and purification of GST-STAT3
The pGEX-KG plasmid expressing STAT3 was transformed into BL21 codon plus bacteria and protein expression was induced with 0.2 mM IPTG in the presence of 3% ethanol in LB broth at 251C for 20 h. Bacterial cells were then harvested and GST-STAT3 was purified by batch affinity purification with glutathione agarose beads (Sigma) following the manufacturer's instructions. Free glutathione was removed by dialysis after protein preparation. Concentration of the GST-STAT3 protein was determined by Bio-Rad Protein Assay. The purified protein was snap-frozed with liquid nitrogen and stored at À801C until use.
In vitro kinase assay Cells were transfected with vector, Brk-V5, or Brk K219M-V5 plasmids and harvested after 48 h. Cells were lysed in 50 mM Tris (pH 7.5) buffer containing 150 mM NaCl, 1% NP-40, 5 mM EDTA, 10% glycerol, 1 mM PMSF, and protease inhibitor cocktail (Sigma) and cell debris were removed by centrifugation. Following pre-clearance of the lysates with Protein G agarose beads, 1 mg total protein was used in each assay reaction and incubated with 2 mg anti-V5 or MOPC antibodies and 15 ml Protein G agarose beads at 41C with gentle agitation overnight. Purified GST-STAT3 proteins were incubated with glutathione agarose beads in 1 Â PBS with 1 mM PMSF at 41C with gentle agitation. The two beads were washed in buffer five times and equilibrated with kinase buffer containing 25 mM HEPES (pH 7.3), 150 mM NaCl, 5 mM MgCl 2 , 5 mM MnCl 2 , 1 mM CaCl 2 , 10 mM NaF, and 200 mM Na 3 VO 4 . The phosphorylation assay was performed with 15 ml glutathione agarose beads with approximately 20 mg immobilized GST-STAT3 proteins, incubated with 15 ml Protein G agarose beads with immunocomplexes in a 30 ml kinase buffer reaction supplemented with 20 mM ATP at 301C with gentle agitation for 1 h. The mixed beads were collected and proteins were eluted with SDS-loading dye followed by SDS-PAGE and Western blot analysis. In addition, 20 mg GST-STAT3 proteins immobilized on glutathione agarose beads were incubated with different amounts of purified recombinant Brk isolated from baculoviral expression and immobilized on Talon beads in the above condition (Qiu & Miller, 2002) . Phosphorylation of STAT3 was detected by Western blot analysis with specific STAT3 phosphotyrosine antibody.
